The IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by IoT solutions developer Samsara (IOT). 14 SPACs also went public. The pipeline got a boost, with six IPOs and three SPACs submitting initial filings. Samsara (IOT) priced at the high end to raise $805 million at a $12.4 billion market cap....read more
Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, raised $36 million by offering 3.1 million ADS equivalents, including 0.7 million offered exclusively to existing shareholders in Italy, at $11.50, within the range of $10.50 to $12.50. The company offered 0.5 million more ADS equivalents than anticipated. Genenta is engaged in the...read more
Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, announced terms for its IPO on Wednesday. The Milan, Italy-based company plans to raise $30 million by offering 2.6 million ADS equivalents, including 1 million being offered exclusively to existing shareholders in Italy, at a price range of $10.50 to $12.50. At the...read more
Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, filed on Wednesday with the SEC to raise up to $35 million in an initial public offering. Genenta is engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. Its lead candidate, Temferon, was developed using its novel biologic platform...read more
US IPO Weekly Recap: 6 IPOs debut ahead of the shortened holiday week
The IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by IoT solutions developer Samsara (IOT). 14 SPACs also went public. The pipeline got a boost, with six IPOs and three SPACs submitting initial filings. Samsara (IOT) priced at the high end to raise $805 million at a $12.4 billion market cap....read more
Italian solid tumor biotech Genenta Science prices upsized US IPO at $11.50 midpoint
Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, raised $36 million by offering 3.1 million ADS equivalents, including 0.7 million offered exclusively to existing shareholders in Italy, at $11.50, within the range of $10.50 to $12.50. The company offered 0.5 million more ADS equivalents than anticipated. Genenta is engaged in the...read more
Italian solid tumor biotech Genenta Science sets terms for $30 million US IPO
Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, announced terms for its IPO on Wednesday. The Milan, Italy-based company plans to raise $30 million by offering 2.6 million ADS equivalents, including 1 million being offered exclusively to existing shareholders in Italy, at a price range of $10.50 to $12.50. At the...read more
Italian solid tumor biotech Genenta Science files for a $35 million US IPO
Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, filed on Wednesday with the SEC to raise up to $35 million in an initial public offering. Genenta is engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. Its lead candidate, Temferon, was developed using its novel biologic platform...read more